Ricoh Company Ltd. has entered a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited for access to the CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.
 
CRISPR/Cas9 is designed to modify targeted genome sequences with ease. The technology is an essential tool in drug discovery research and finds application across various fields.
 
The goal of the agreement is to predict the mechanism of action of candidate drugs for patients with varied genetic backgrounds and to improve the speed and efficiency of mRNA design by combining these core technologies with CRISPR/Cas9 genome editing technology. Through manipulations such as genetic editing of cells to enhance or diminish specific functions, it becomes possible to create highly reliable disease models, including those for rare diseases.
 
This advancement is anticipated to lead to shorter drug development timelines and increased success rates.